Bispecific T cell Engaging Receptor Molecules
T cell receptor (TCR) Bispecifics are biologics that leverage the body’s immune system by redirecting and activating the T cell response towards cancer cells expressing specific tumor targets.
Mode of Action
Immatics' novel T cell Engaging Receptors (TCER™s) are soluble fusion proteins that have two binding domains:
An affinity-maturated and highly selective TCR domain that recognizes and binds to a tumor-specific peptide target presented in the context of HLA class I receptor and a T-cell recruiting antibody domain directed against CD3 or other immuno-modulating T-cell surface proteins. The design of these novel biologics allows T cells to become activated and attack the tumor, regardless of the T cells’ intrinsic specificity.
Engineering and Manufacture
TCER™ molecules are based on affinity-enhanced TCRs and Immatics' proprietary Bispecific platform. The bispecific molecules are subject to XPRESIDENT® guided on- and off-target toxicity screening to identify candidates without off-tumor activity. The selected candidates are then engineered to have superior biophysical properties. These include excellent solubility and stability, as well as desirable pharmacokinetic profiles.
TCER™ molecules are easily produced and scaled up in mammalian host cells. These biotherapeutics are then purified and refined using processes that are compatible with cGMP requirements.